Palatin Technologies, Inc. (PTN) |
|
4.22 0.01 (0.24%)
|
11-25 13:00 |
|
Open: |
4.35 |
Pre. Close: |
4.21 |
|
High:
|
4.35 |
Low:
|
4.12 |
|
Volume:
|
9,068 |
Market Cap:
|
44(M) |
|
|
|
Technical analysis |
as of: 2022-11-25 1:59:46 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 6 One year: 6.83 |
| Support: |
Support1: 3.99 Support2: 3.31 |
| Resistance: |
Resistance1: 5.13 Resistance2: 5.84 |
| Pivot: |
4.39  |
| Moving Average: |
MA(5): 4.22 MA(20): 4.59
MA(100): 5.9 MA(250): 8.44 |
| MACD: |
MACD(12,26): -0.4  Signal(9): -0.4 |
| Stochastic oscillator: |
%K(14,3): 14.8 %D(3): 13.9 |
| RSI: |
RSI(14): 40.5 |
| 52-week: |
High: 17 Low: 0.27 |
| Average Vol(K): |
3-Month: 85 (K) 10-Days: 30 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PTN ] has closed above bottom band by 32.0%. Bollinger Bands are 70.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 33 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
4.22 - 4.24 |
4.24 - 4.26 |
|
Low:
|
3.97 - 3.99 |
3.99 - 4.01 |
|
Close:
|
4.18 - 4.21 |
4.21 - 4.24 |
|
Company Description |
|
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a peptide mimetic molecule with amino acid mimetic structure and amino acids properties; and L8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey. |
Headline News |
Sat, 26 Nov 2022
U.P. Yoddhas vs Patna Pirates, Pro Kabaddi 2022 Season 9, LIVE Streaming details: When and where to watch U... - Zee News
Fri, 25 Nov 2022
Where Does Palatin Technologies, Inc. (PTN) Stock Fall in the Biotechnology Field After It Is Lower By -2.76% This Week? - InvestorsObserver
Thu, 24 Nov 2022
Seaport Res Ptn Weighs in on Bread Financial Holdings, Inc.'s FY2022 Earnings (NYSE:BFH) - MarketBeat
Wed, 23 Nov 2022
Helmerich & Payne, Inc. (NYSE:HP) Forecasted to Earn Q1 2023 Earnings of $0.83 Per Share - MarketBeat
Wed, 23 Nov 2022
Seaport Res Ptn Comments on Dominion Energy, Inc.'s FY2023 Earnings (NYSE:D) - MarketBeat
Tue, 22 Nov 2022
Duke Energy (NYSE:DUK) Downgraded by Seaport Res Ptn to "Sell" - MarketBeat
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: AMEX |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
231 (M) |
|
% Held by Insiders
|
2.2711e+008 (%) |
|
% Held by Institutions
|
4.3 (%) |
|
Shares Short
|
4,770 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-3.22e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
-0.35 |
|
EPS Est Next Year
|
-0.06 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-12 |
|
Return on Assets (ttm)
|
429 |
|
Return on Equity (ttm)
|
-25.1 |
|
Qtrly Rev. Growth
|
259440 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
-72.13 |
|
EBITDA (p.s.)
|
-1.56e+007 |
|
Qtrly Earnings Growth
|
-0.2 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-33 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.06 |
|
Price to Cash Flow
|
18.87 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
1.149e+007 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
